Amgen EVP of Operations Esteban Santos sold 30,501 shares on February 26, 2026, at $379.12 per share, for a total value of about $11.56 million. A sale of this size is notable because it represents a meaningful reduction in an executive’s personal exposure to the stock and is large enough to draw attention from investors who track insider behavior. Santos oversees operations, a senior role tied to manufacturing, supply chain, and execution—areas that can influence performance but typically don’t involve setting overall corporate financial guidance. Insider sales can happen for many routine reasons such as diversification, taxes, or planned selling programs, so the transaction alone doesn’t necessarily signal anything about business conditions. Still, investors often watch whether senior leaders are buying or selling around the same time. This trade also fits within a broader pattern of recent insider selling at Amgen, with another executive sale reported in the prior week (VP of Finance & CAO Matthew C. Busch on February 19, 2026). With no insider buys noted in the last 30 days in the information provided, the near-term activity skews toward selling, which can be worth monitoring alongside upcoming company disclosures.